Pre-IPO
2
Statements in this document relating to future status, events, or circumstances,
including but not limited to statements about plans and objectives, the progress and
results of research and development, potential product characteristics and uses,
product sales potential and target dates for product launch are forward looking
statements based on estimates and the anticipated effects of future events on current
and developing circumstances.
Such statements are subject to numerous risks and uncertainties and are not necessarily
predictive of future results. Actual results may differ materially from those anticipated in
the forward-looking statements. Senfina may, from time to time, make additional written
and oral forward-looking statements, including statements contained in the company’s
filings with the regulatory bodies and our reports to shareholders. The company
assumes no obligation to update forward-looking statements to reflect actual results,
changed assumptions or other factors.
~
FORWARD-LOOKING STATEMENTS
• EXECUTIVE & MANAGEMENT TEAM
• COMPANY OVERVIEW
• MARKET OVERVIEW AND UNMET NEEDS
• SENFINA OVERALL SERVICES
• SENFINA PRODUCTION
• PRODUCTS
• SENFINA PROJECTS
• TRADING & DISTRIBUTION CHANNELS
• FINANCIALS & INVESTMENTS
• ALTERNATIVE MARKET WITH VETERINARY PRODUCTS
• PROPOSAL
EXECUTIVE &
MANAGEMENT TEAM
4
5
INTRODUCTION
Senfina stands as a unique Contract Manufacturing and Development Organization
(CMDO) that has been meticulously designed from inception to adhere to a
comprehensive 360-degree Good Manufacturing Practice (GMP) framework. Our
company possesses not only the necessary factory capacity but also the skilled
personnel and industry expertise to efficiently execute operations within required
timelines, effectively meeting the demands of the market.
Unlike traditional CMDOs, Senfina is not confined to a single product, which enables us
to seize diverse opportunities in producing other vital and highly sought-after medicines.
The significance of the CMDO model has become evident due to the future market
demand.
As an active participant in the market, our company introduces progressive approaches
and extends support to small-scale drug developers in scaling up their production
capabilities, thus enhancing the accessibility of important treatments.
Already at present, Senfina has secured several customers with an anticipated demand
of 1.7 billion doses of medical liquids starting from 2023. A portion of this demand is
being fulfilled by the operational trading wing of Senfina, which originated from its
predecessors, Synergy Forte and Interport.
~
Ray Patel
Chairman
Shakir Mughal
CEO
We pride ourselves on being a flexible company equipped with modern manufacturing
capabilities and scientific potential, enabling us to stay abreast of current trends and
provide solutions to the most complex challenges.
6
Jean Luc Eich
Managing Director
BOARD OF DIRECTORS
Ray Patel
Chairman
Shakir Mughal
CEO
Dr. Carin Heringa
Board Member
Dr. Tom Pulles
Head Medical
Jayaram Sathyanarayana
Board Member
7
Jean Luc Eich
Managing Director
Sven Floer
CFO
MANAGEMENT TEAM
Attila Santa
Head Business Unit
Yuliya Chepurna
Interface Manager&HR
Susanne Arndgen
Head of Engineering
Sofia Pugna
Head of QA
Roxana Begu
Head of Production
Stefanie Erol
Head HSE
Edit Santa
Head Accounting
Dr.Nandor Santa
Head Development
8
Attila Santa
Edit Santa
Shakir Mughal
Dr. Nandor Santa
Yuliya Chepurna
Jean Luc Eich
Alexandra Epure
WE ARE SENFINA
WE ARE SENFINA
9
MANAGEMENT TEAM
IN BRASOV
10
Products are
currently produced
Currently 15 Products for OSD are
under registration, 9 products in different
strength for OSD and 17 liquid products
(vaccines) are planned for future production
Committed to a more
sustainable future
Locations:
Switzerland
United Kingdom (UK),
United Arab Emirates (UAE)
Romania
4
Employees spread in
over 4 countries
250
> 40 products
> 20 products
100 %
SENFINAIN NUMBERS
COMPANY OVERVIEW
11
612
New Standard in CDMO
Services
A Wealth of
Experience
Compelling Financial
Proposition
Innovative capabilities, processes and
design, specifically designed for vaccines
and other pharmaceutical forms
Modular production design that allows a
new level of flexibility and quality
Sophisticated design allows production
licensing to external partners, making
local production in emerging markets
feasible
Decades of experience with legacy com-
panies and international senior leadership
Highly capable team with strong track
record in pharmaceutical companies and
CDMO services
Established relationships with key public
health stakeholders and customers
Significant order book already secured
prior to capital investment
Early focus on capital investment in infra-
structure offers low-risk investment
opportunity
Attractive stock price offering with rapid
roadmap to IPO
Senfina is a leading pharmaceutical technology company,
aiming to become global full service CDMO for vaccines and
other pharmaceutic forms
A new company with decades of history and key relationships
with stakeholders
13
15
MARKET OVERVIEW&
UNMET NEEDS
High demand for local vaccine production in Africa and across Emerging Markets
Emerging markets are especially impacted by capacity
restraints
Foreign production capacity often diverted away from
emerging markets to higher priced countries
COVID-19 response has cannibalized capacity used for
supplies for African and emerging markets
Shortages of vaccines have been reported as an increasing
concern in the European Union (EU) and globally
Anticipated increased number of countries will
report stock outs due to COVID-19
Number of Countries reporting Vaccine Stock Out
“ “[…} Between now and 2040,
we need to shift the paradigm so
that we can manufacture
67
66
57
54
50
65
73
70
69
2010 2011 2012 2013 2014 2015 2016 2017 2018
Dr. J. Nkengasong
Director, Africa CDC
atleast 60% of our vaccines
16
COVID 19
16%
Influenza A
12%
HIV
10%
Malaria
6%
RSV
5%
Pneumonia
5%
Pertussis
4%
Tetanus
4%
Poliomyelitis
4%
Pneumococal
4%
Diptheria
4%
Hep B
3%
Influenza B
3%
Other
20%
�61
�125
2021 2022 2023 2024 2025 2026 2027 2028
Strong underlying market growth drivers in key strategic CDMO segments
Vaccine Candidates
2
currently in development
254
Vaccine Candidates
Global Market Value - Vaccines
1
� billion
Long-term vaccine demand expected to grow with higher vaccination
rates in emerging markets and on-going COVID-19 response growth
Hundreds of new vaccines candidates are in development
for both emerging and established vaccination
disease targets
17
18
Trend for further outsourcing of manufacturing by big pharma as well as
emerging Biotech growth companies
COVID 19 vaccine production dominating demand
Non-Covid vaccine production deprioritized
Long and complex manufacturing including multiple
quality controls
Unpredictability of global demand
Growth in personalised medicine & gene-targeted
therapeutics
Increasing need for flexible, small batch production lines
$184
$290
2021 2022 2023 2024 2025 2026 2027
Projected Market Growth
CDMO services 2 $ billion
Trend to outsource to CDMO, market projected to
increase 8-10% growth for Vaccine CDMO services
19
Insulin market expected to significant increase due to increases in
Diabetes associated with COVID-19
• Demand for insulin expected to increase significant in association
with COVID-19
• Basic access to insulin and diabetic treatments in Africa still limited
• Significant need expected for further insulin capacity, especially for
emerging markets
With large and growing numbers of people worldwide
infected with SARS-CoV-2,10 any COVID-19-related
increases in diabetes incidence could lead to
unprecedented cases of diabetes worldwide”
Dr. R. Glavan,
Former Minister of Health, Moldova
Projected Global Diabetes Cases
in Millions
537
643
783
2020 2025 2030 2035 2040 2045
20
High demand for local insulin production in Middle East and across
Emerging Markets
Current levels of insulinaccess are disproportionately inadequate in the African, Asian. The regions projected to increase
insulin use most if access were improved.
Diabetes is rising worldwide but it is reaching an epidemic level in the Middle East countries. The Middle East and North
Africa region has the highest percentage (24.5%) of diabetes-related deaths in people of working age in the world.
21
SENFINA OVERALL
SERVICES
22
Our Services –A compelling value proposition for established and growing
pharmaceutical companies
Senfina provides a brand independent CDMO service that caters vaccine,
other liquids and solid forms to pharmaceutical companies as well as
innovative developers that need a production partner for their products
Specialty CDMO services Production Localization &
Licensing
Business Development
GMP Production:
API for bulk and small batch requirements
Fill & Finish in various formulations : vial,
PFS
OSD production
Packaging:
Customized packaging solutions based on
each client's needs
Primary & secondary packaging, serialize
and processing
Logistics:
Full warehousing and distribution capabilities
Facility Design Licensing:
Licensing of Senfinamodular production
design for local partners
Advisory in set up and production
planning
API Supplier:
API supply for local production partners
Infrastructure Financing
Capital pool to support local partner
production
Senfina is planning to acquire biotech
company to develop drugs.
The development team is already in
contact with different companies
Due to increasing diabetic worldwide as
a result of COVID-19 infection (ref: WHO) ,
Senfina has acquired OSD production site
in Romania to expand product portfolio
and deploy solid insulin production in the
EU.
Key Features Benefits to the Customer
Multiple vaccines formulations & filling at the same time in PFS or vials
•Highest BPE ( bioprocessing equipment ) standard and no contamination risk
•Wide range of batch sizes (20l-500l)
•High percentage of IPC at each production line
•Ability to produce a broader range of vaccines in more efficient approaches
•Production of more SKU’s based on market needs
•Efficiently run small batch sizes for clinical development and personalized medicine
•High-speed, automatic fill and finish lines
•Flexible production line design that can accommodate most customer needs
•Achieving highest standards of safety for employees, products, and environment.
Formulation, Fill & Finish
Modular set up of production line
Broad range of filling and packaging
solutions (i.e. vials, pre-filled syringes,
capsules, tablets, sachets)
Design utilizing reliable technology
Design &
Development
Partner
Our modular approach in production brings a new standard in flexible production lines that allow
a rapid setup of the production line and the ability to produce wide range of batches and
broader spectrum of products within a production cycle.
SGE
PHARMA CONSULTING
Our production design, created specifically for vaccines
pharmaceutical liquids and other medical forms
25
23
SENFINA PRODUCTION
25
Acquisition of an existing OSD production site in Romania marked
one of Senfina’s 1st partnered venture in the EU market
23 Products in existing portfolio
19new products submitted
10 main customers
28,000 sqm
Flexible production line
Sustainable engineering
Full-service contract development and
production of solid dosage forms
(tablets, capsules and sachets).
Full-service contract production of
vaccines (Inactivated, Subunit, Toxoid,
Conjugated, Recombinant vector, mRNA, DNA)
600,000,000 Tablets/year
60,000,000 Vials/year
30,000,000 PFS/year
OSD 2025
Fill and Finish 2026
Facility Facts and Figures
Size
Design Principles
Product Capabilities
Production Capacity
after capability
expansion
Expansion completion
26
PRODUCTS
27
28
Investor Presentation |
Confidential 28
EXISTING PRODUCT PORTFOLIO
29
PRODUCTS IN PIPELINE / UNDER REGISTRATION
30
Investor Presentation |
Confidential 30
EXISTING SERVICES
31
Investor Presentation |
Confidential 30
Selected New Product, Strenght & Form (OSD)
32
SELECTED NEW PRODUCT (F&F LIQUIDS)
33
SENFINA PROJECTS
34
Senfina’s production design allows the final stages of production
to be completed in EU and emerging markets
Senfina remote production licenses
allow local partners in emerging
markets to establish “Fill and Finish”
facilities
Senfina operates as:
• Licensor of Production Design
• Integrated API supplier/partner
• Financing for infrastructure through
35
Production site in UAE will be another significant partnered venture
Facility Facts and Figures
Size 30,000 sqm
Design Principles Flexible production line
Sustainable engineering
Product Capabilities Fill & finish & OSD production
Insulin
Production Capacity
per annum
Vials: 50,000,000
PFS: 30,000,000
Insulin pen: 50,000,000
1
st
line in operation 2028
Ground -breaking 2025
UAE
Phase 2
36
CDMO Campus in Basel-land Switzerland to expand capacity and
fuel growth of Senfina
Facility Facts and Figures
Size 35,000 sqm
Design Principles Vaccine production center including social
areas / Warehousing / Energy buildings
With Sustainable engineering
Product Capabilities 2 API production facilities
All Major Vaccine Technologies
• Inactivated vaccines
• Subunit
• Toxoid
• Conjugated
• Recombinant vector
• mRNA
• DNA
Production Capacity
per annum
API: 25,500- 40,000 kg
1
st
line in operation 2030
Ground -breaking 2026
Liestal, Basel
Phase 4
37
Our Near-and Medium-Term Strategy is Focused on Growth through
Capacity Expansion
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Near -term:
Establish core European
infrastructure and business
Expand capacity for industry
customer base
Phase 1a +1b –OSD and Fill and Finish
facilities in Brasov Romania
Phase 3 –Capacity Expansion in Basel Liestal
Phase 4 –Broad Expansion into other Emerging
Markets
Markets in plan: Tajikistan, Nigeria, India
Medium -term:
Confirm licensing and API supplier
business model
Long -term:
Expand capabilities and service
offering through M&A and
partnering
Expand capacity build across Africa
and other emerging markets
Phase 2b –Insulin production facility in UAE
Phase 2a: API Production in UAE ( until BSL 2 )
38
Trading & Distribution channel
with Interport ltd UK
(Member of Senfina Group)
We are a UK based pharmaceutical wholesalers established in
1982 specializing in Parallel Imported Products, Generics, OTC
products throughout the UK, Europe, Africa and most of the world
We are fully licensed to operate, and we are regulated by the
MHRA
OUR TRADING COMPANY
In the realm of veterinary products, it is widely acknowledged
that prices tend to be high in Europe and the USA, largely due
to the presence of certain manufacturers enjoying a monopoly
In this regard we plan a proactive approach in manufacturing
veterinary medicines and vaccines for the Indonesian market
within our state-of-the-art facility located in Romania. This
strategic decision promises to revolutionize the price point
structures, making them significantly more favorable for our
valued customers in Indonesia. Furthermore, the establishment
of a seamless and uninterrupted supply chain will ensure
smooth imports and supplies, meeting the needs of the
Indonesian veterinary healthcare sector efficiently and
effectively.
39
40
Financials & Investments
41
Phase Ia: Manufacturing Site Acquisition Romania &
Extension plan by 2024 (OSD)
€ 15 MM
FEES & CONTINGENCIES
2023
PHASE 1 -Manufacturing site
Acquisition
Total MM €
2023
Fees & Contingencies
€ 15
2024Other Furniture € 2
Computer & IT € 2
Electric & Automation € 3
Energies & Equipment € 10
Licences & Permits € 10
Fees & Contingencies € 5
Buildings & HVAC € 1 0
Machinery
€ 20
TOTAL
€ 77
Acquisition cost is € 15 MM
Extension cost is € 62 MM
Fees &
Contingencies,
€ 15
Other
Furniture, €2
Computer &
IT, €2
Electric &
Automation, €3
Energies &
Equipment, € 10
Licences &
Permits, €10
Fees &
Contingencies,
€ 5
Buildings &
HVAC, € 10
Machinery, € 20
42
Phase Ib: New Fill & Finish Facility in Brasov, Romania
PHASE 1 - MM €
Other Furniture € 10
Computer & IT € 4
Electric & Automation € 20
Energies & Equipment € 28
Fees & Contingencies € 28
Buildings & HVAC € 35
Machinery € 45
TOTAL € 170
Total Phase I investment is € 170 MM
Other Furniture, € 10
Computer & IT, € 4
Electric &
Automation, € 20
Energies &
Equipment, € 28
Fees &
Contingencies , € 28
Buildings & HVAC ; € 35
Machinery; € 45
43
Phase IIa: New Site CAMPUSin UAE for API production ( until BSL 2 )
Total Phase IIainvestment is € 510MM
Other Furniture, € 25
Computer & IT, € 15
Electric &
Automation,
€ 40
Energies & Equipment ,
€ 120
Fees &
Contingencies
,
€ 50
Buildings & HVAC, € 150
Machinery, € 100
Labs, € 10
PHASE 2 API Production - MM €
Other Furniture
Computer & IT
Electric & Automation
Energies & Equipment
Fees & Contingencies
Buildings & HVAC
Machinery
Labs
TOTAL
€ 25
€ 15
€ 40
€ 120
€ 50
€ 150
€ 100
€ 10
€ 510
44
Phase IIb: Extension in UAE for further Fill and FinishTotal Phase IIb
investment is € 300MM
PHASE 2 - Insulin Production - MM €
Other Furniture
Computer & IT
Electric &
Automation
Energies &
Equipment
Licences & Permit
Fees &
Contingencies
Buildings & HVAC
Machinery
Labs
TOTAL
€ 15
€ 10
€ 25
€ 30
€ 10
€ 40
€ 80
€ 80
€ 10
€ 300
Other Furniture, € 15
Computer & IT, € 10
Electric &
Automation, € 25
Energies &
Equipment, € 30
Licences &
Permit, € 10
Fees &
Contingencies, € 40
Buildings & HVAC, € 80
Machinery, € 80
Labs, € 10
45
Phase III: Capacity Expansion in Basel –LiestalTotal Phase III
investment is € 727 MM
Others
Furniture
4%
Computer
& IT
2%
Electric &
Automation
6%
Energies &
Equipment
12%
Licences &
Permits
3%
Fees &
Contingencies
12%
Buildings &
HVAC
36%
Machinery
25%
PHASE 2a API Production - MM €
Others
Furniture
Computer
& IT
2%
Electric &
Automation
5%
Energies &
Equipment
11%
Licences &
Permits
2%
Fees &
Contingencies
12%
Buildings &
HVAC
38%
Machinery
26%
PHASE 2b Production 2 - MM €
Administration
Building
33%
Parkings
Building
7%
Warehouse
Building
35%
Energy
Building
14%
Restaurant
Building
6%
Pforte /
Entrance
1%
Others
4%
General Site Investments - MM €
PHASE 2a API Production - MM €
Other Furniture
€ 12
Computer & IT
€ 5
€ 18
€ 38
€ 10
€ 40
€ 116
€ 82
€ 321
PHASE 2b Production 2 - MM €
€ 12
€ 5
€ 14
€ 32
€ 6
€ 35
€ 107
€ 75
Other Furniture
Computer & IT
Electric & Automation
Energies & Equipment
Licences & Permit
Fees & Contingencies
Buildings & HVAC
Machinery
TOTAL
Other Furniture
Computer & IT
Electric & Automation
Energies & Equipment
Licences & Permit
Fees & Contingencies
Buildings & HVAC
Machinery
TOTAL € 286
General Site Investments - MM €
Administration Building € 40
Parkings Building € 8
Warehouse Building € 42
Energy Building € 17
Restaurant Building € 7
Pforte / Entrance € 1
Others € 5
TOTAL € 120
4%
46
Total Investment Plan including Acquisitions: 1.8 Bn €
247
810
727
0
100
200
300
400
500
600
700
800
900
Phase I Phase II Phase III
MM, €
Total EUR Bn
Phase I
Brasov, Romania
Phase II
Dubai, UAE
Phase III
API Production in Switzerland
47
Senfina Investment Plan – EUR MM
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Total (right axis)
2 3 40 242.5 310 411.5 235 260 240 44
Overall pre-cost Investments
2 2
Investments Senfina Romania
0.5 24 62 60 100.5
Investments Senfina UAE
15 180 240 260 115
Investments Senfina Switzerland
0.5 1 0.5 10 51 120 260 240 44
0
50
100
150
200
250
300
350
400
450
0
50
100
150
200
250
300
EUR, MM
Senfina Investment Plan
Total (right axis) Overall pre-cost Investments Investments Senfina Romania
Investments Senfina UAE Investments Senfina Switzerland
48
Senfina Revenue Plan – EUR MM
0
100
200
300
400
500
600
700
800
900
0
50
100
150
200
250
300
350
400
2022 2023 2024 2025 2026 2027 2028 2029 2030
EUR MM
Senfina Revenue Plan
TOTAL (right axis) Revenues Senfina Romania Revenues Senfina UAE Revenues Senfina Switzerland
49
SefinaRevenue vs Investment -EUR MM
2021 2022 2023 2024 2025 2026 2027 2028 2029 2030
Total Investment
2 3 40 242.5 310 411.5 235 260 240 44
Total Revenue
0 8 26 45 113 158 241 660 835
0
100
200
300
400
500
600
700
800
900
Euro, MM
Senfina Revenue via Investments
Total Investment Total Revenue
50
2021-2030 Total Investment vs Revenue –EUR MM
1,788
2,086
1600
1650
1700
1750
1800
1850
1900
1950
2000
2050
2100
2150
Total Investment Total Revenue
Total EUR Bn
Alternative Markets /
Veterinary products
Proposal for Indonesia
51
52
List of product categories which can be produced in Romania now
ANTIPARASITICS: Medications used to treat parasitic infections, such as anthelmintics (e.g.,
ivermectin) and antiprotozoals (e.g., metronidazole), may be used in both humans and animals.
CORTICOSTEROIDS: Corticosteroids, such as prednisone and dexamethasone, have applications in
both human and veterinary medicine for their anti-inflammatory and immunosuppressive properties.
NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS): NSAIDs like aspirin, ibuprofen, and
naproxen are commonly used in both human and veterinary medicine to alleviate pain and reduce
inflammation.
ANTIFUNGALS: Certain antifungal medications, such as fluconazole and ketoconazole, may be
prescribed for both humans and animals to treat fungal infections.
53
List of product categories which can be produced
in Romania after revamp
Following an investment in creating a manufacturing space for producing antibiotics for
veterinary use we will be able to cover various pharmaceutical forms to suit different animal
species, sizes, and administration needs.
Some common pharmaceutical forms of antibiotics used in veterinary medication include:
1.Oral Tablets and Capsules: Antibiotics are often formulated into oral tablets or capsules, making
it convenient to administer to animals that can take medication orally. These forms may be
designed to be swallowed whole or mixed with food.
2.Oral Liquids: Antibiotics can be formulated as liquid suspensions or solutions for oral
administration. These forms are particularly useful for animals that may have difficulty
swallowing tablets or capsules.
3.Injectable Solutions: Antibiotics can be prepared as sterile injectable solutions for
administration by intramuscular (IM) or subcutaneous (SC) injection. Injectable antibiotics allow
for rapid and effective delivery of the medication.
4.Topical Creams and Ointments: Certain antibiotics are formulated as topical creams or
ointments for the treatment of localized skin infections or wounds in animals.
5.Otic (Ear) Preparations: Antibiotics in otic form are used to treat ear infections in animals. These
formulations are designed for safe and effective application in the ear canal.
6.Ophthalmic (Eye) Preparations: Antibiotics in ophthalmic form are used to treat eye infections in
animals. They are formulated for safe application to the eye.
7.Intravenous (IV) Solutions: Some critically ill animals may require IV administration of
antibiotics. IV solutions are prepared to ensure accurate dosing and rapid delivery of the
medication.
8.Intramammary Preparations: Antibiotics formulated as intramammary preparations are used to
treat mastitis in lactating animals. These formulations are applied directly into the mammary
gland.
Many of the above technologies could be also extended for corticosteroids too.
ANTIBIOTICS: Certain antibiotics are used in both human
and veterinary medicine to treat bacterial infections.
Examples: include penicillin, tetracycline, and
fluoroquinolones
VETERINARY VACCINES: NovibacRabies, NovibacDHP,
Leptospira (Leptoferm), Vanguard Plus S
DIABETICS: Sitaslipin, Aloglipin,
Empagliblozin
ALLERGY: Desloratadin, Fexofenadine
HYPERTENSION: Fosinopril, Felodipine
54
Senfina Licenses
CERTIFICATE OF GDP COMPLIANCE OF A WHOLESALE DISTRIBUTOR № UK WDA(H) 6176 INSP GDP
0017-421408/6176
A Certificate of GDP (Good Distribution Practice) Compliance is a document issued to a wholesale distributor in the
pharmaceutical industry, indicating that the distributor has met the requirements and standards of GDP.
WHOLESALE DISTRIBUTION AUTHORIZATION (WDA) ISSUED BY MHRA №6176
Wholesale Distribution Authorization (WDA) is a license granted to Senfina that allows it to engage in wholesale
distribution activities of pharmaceutical products or medicinal goods. It is a regulatoryrequirement and is issued by the
MHRA that is responsible for overseeing the distribution of pharmaceuticals.
The purpose of a Wholesale Distribution Authorization is to ensure that Senfina complies with certain standards and
regulations to safeguard the quality, safety, and efficacy of pharmaceutical products throughout the supply chain.
A certificate of GMP (Good Manufacturing Practice) Compliance of a Manufacturer is a document that certifies that a
manufacturing facility complies with GMP standards. GMP is a set of quality assurance guidelines and regulations that
ensure pharmaceutical, biotechnology, and medical device manufacturers maintain consistent and high quality
production practices. Obtaining a Certificate of GMP Compliance is crucial for manufacturers as it demonstrates their
commitment to producing safe and effective products
MANUFACTURING AND IMPORTATION LICENSE | HEALTH AND SAFETY LICENSE | ENVIRONMENT
PROTECTION LICENSE CONTROLLED SUBSTANCES LICENSE | LABOR PROTECTION CERTIFICATE
WASTEWATER TREATMENT CERTIFICATE
55
OUR COLLABORATION PROPOSAL
1 2
4
New production
facility in Indonesia
Producing and delivering
our Products
Organization & Delivery
other needs
With our internally world wide recognized
engineering competences, we aim to plan,
develop, and ensure the construction of a
new facility in your country through a joint
venture.
This facility can be utilized for the
production of veterinary products as well
as essential human medicines.
Senfina is interested in entering a joint
venture to produce and deliver our existing
products to Indonesia, if there is a demand
for these products in the market.
3
Preparation / Revamping
existing production
Senfina is ready to organize the revamp of
an existing building in our Romanian
facilities to produce essential veterinary
products needed in Indonesia
Senfina, through our parallel imports and
distribution channels, aims to provide other
products (both human and veterinary
medicines) to Indonesia.
56
Roadmap To Intial Public Offering
2022 2023 2024 2025 2027
Consolidation / Restructuring
Development
Consolidation
Participation
Listing & Trading
Listing London Stock Exchange
Emissions (Including synthetic)
WOOD PLC and Senfina
To develop 1 F&F Site
and one API Production
New capital raising,
acquisitions and
restructuring.
Acquisition of Santa Pharma
Romania
Pre trading
Market making phase
exclusively to friends
or known partners /
investor, Revamp Santa
Pharma
Registration of the stock
exchange prospectus with
current consolidation plan,
General Assembly approving
going public, MarketingMaking
Phase, OTC Trade.
Commence Construction in
Basel Project Site
Capital Building-up / new accounting
Rating improvement thanks to paid
loans. Entry on the UK primary marketing.
Decision for the lead manager to go public,
Filing Prospectus to LSE and going public
Consolidated Assets / Fixed Income
in securitized form as part of a separate security facility
(captive) possible with the involvement of reinsurance
Performance On Demand Guarantee: est 250 million
for convertible bonds.
Spin Offs:
Campus development Reinach AG / Basel- International
listing ( cross listings) on other regulated markets
Convertible Bond 50 Mio
Strategic Investor 125 Mio
Country License UAE 75 Mio
Capital raising (Pre IPO) 30 Mio
Security
Extended Exit Stretegy
Portfolio construction
Pre IPO / Market Making / IPO
www.senfina.uk
DISCLAIMER
This presentation is intended exclusively for the person or entity to which it is provided and contains information that is confidential and proprietary to Senfina Holding Ltd. It is strictly
not for further distribution and must not be copied, reproduced, distributed, or passed to others at any time without the prior written consent of Senfina Holding Ltd.
The material provided in this presentation has been prepared for informational purposes only and does not constitute an offer to sell or the solicitation of an offer to purchase any
security, product, or service. It does not constitute investment, legal, accounting, tax, or other professional advice, and recipients should consult with their own professional advisors
before taking action based on this information.
The information herein is provided "as is" and Senfina Holding Ltd makes no representation or warranty of any kind regarding the accuracy, adequacy, validity, reliability, availability, or
completeness of any information in the presentation. The company, its affiliates, and their respective officers, directors, employees, and agents expressly disclaim any and all liability that
may be based on such information, errors therein, or omissions therefrom.
The information presented includes forward-looking statements that involve risks and uncertainties, and actual results may differ materially from those discussed. Senfina Holding Ltd
assumes no obligation to update or revise any forward-looking statements made herein or any other forward-looking statements made by the company, whether as a result of new
information, future events, or otherwise.
Prospective investors should not place undue reliance on the forward-looking statements in this presentation. An investment in Senfina Holding Ltd involves substantial risks and
uncertainties. Past performance is not indicative of future results, and no assurance can be given that the company’s future performance will be comparable to past performance or that
the company’s business objectives will be achieved.
Prospective investors are strongly recommended to conduct their own due diligence, including a thorough review of Senfina Holding Ltd business, financial condition, and prospects,
before making an investment decision.
Senfina Holding Ltd reserves the right to amend or replace the information contained herein at any time but has no obligation to update any information provided to the recipient.
